Bausch + Lomb News

Bausch + Lomb Announces Licensing Agreement With Tangible Science For Use Of Tangible Hydra-PEG Custom Contact Lens Coating Technology

In June, Bausch + Lomb, a leading global eye health company, entered into a worldwide licensing agreement with Tangible Science, LLC, a company whose mission is to create technologies that improve the contact lens wearing experience. As part of the agreement, Bausch + Lomb will offer the Tangible Science Hydra-PEG® advanced contact lens coating technology for use with several of its Boston® gas permeable (GP) materials and scleral lenses through its Specialty Vision Products business.


Bausch + Lomb Launches -2.75D Cylinder Power for Bausch + Lomb ULTRA® for Astigmatism Contact Lenses, The Fastest Growing Family of Monthly Planned Replacement Lenses

Also in June, the company announced the availability of Bausch + Lomb ULTRA® for Astigmatism contact lenses in cylinder power of -2.75D, which is available across all power ranges in the portfolio, from +6.00D to -9.00D, making it the only monthly planned replacement lens with this cylinder power available in the fit set. The fastest-growing family of monthly planned replacement lenses, Bausch + Lomb ULTRA for Astigmatism lenses combine MoistureSeal® technology, which helps to maintain 95 percent of lens moisture for a full 16 hours, and OpticAlign™ design, engineered for stability to promote a successful first fit. This latest expansion will allow eye care professionals to fit more of their astigmatic patients with these lenses to provide all-day comfort, stability, and consistently clear vision.


Bausch + Lomb Receives FDA Approval of Extended Wear Indication for Bausch + Lomb ULTRA® Family of Contact Lenses

In May, the U.S. Food and Drug Administration approved the Bausch + Lomb ULTRA® family of contact lenses for extended wear for up to seven days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care professional.


Bausch + Lomb Announces US Launch of Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

Bausch + Lomb announced the introduction of Soothe® Xtra Protection (XP) Preservative Free lubricant eye drops in June, expanding its portfolio of eye health products to meet the growing demand for dry eye symptom relief without the use of preservatives. One of the most common eye conditions in the U.S., dry eye affects more than 140 million Americans, many of whom report a sensitivity to preservatives in eye drops.


Bausch + Lomb Introduces Ocuvite® Blue Light Vitamins

Also in June, the company announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision.


Bausch + Lomb Announces the U.S. Launch of LUMIFY, The First and Only OTC Redness Relieving Eye Drop with Low-Dose Brimonidine

In May, Bausch + Lomb announced the launch of LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. In clinical trials, LUMIFY eye drops demonstrated a strong safety and efficacy profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours.


Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Chewable Vitamins
The company also announced the introduction of PreserVision® AREDS 2 Formula Chewable vitamins in May, which were designed to meet the growing consumer preference for chewable tablets, in a mixed berry flavor. PreserVision AREDS 2 Formula vitamins are the only vitamins that contain the exact levels of six key nutrients recommended by the National Eye Institute.


Bausch + Lomb Signs Agreement with Express Scripts, Inc., Expanding Insurance coverage of Vyzulta™ (Latanoprostene Bunod Ophthalmic Solution), 0.024%

In March, Bausch + Lomb announced an agreement with Express Scripts, Inc. to begin coverage of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%. Under the agreement, VYZULTA is covered under an access position on both the commercial Express Scripts National Preferred and Basic formularies, giving access to an additional 23 million people in the United States. VYZULTA, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.